Revenue from operations took a downtrend from 5925 crores to 5702 crores a degrowth of 4% YOY, & 5% degrowth sequentially.
EBITDA also followed the same path and stood at 1319 crores from 1373 crores YOY, a degrowth of 4% YOY & 3% QOQ
EBITDA margin stood at 23%, growth rate being flat YOY & QOQ.
PAT also tumbled by 1% YOY from 781 crores to 770 crores, a degrowth of 4% QOQ
PAT margin stood at 14%, a slight improvement of 1% YOY & QOQ
Research & Development (R&D) spend at 358 crores, 6.3% of revenues
Net organic capex for the quarter ~US$6.4 crores. Net cash including investments at the end of June 2021 was at US$1.5 million
Constant currency US sales ~ US$36.4 crores.
Free Cash Flow is currently at -10.6 crores for Q1 FY 2022
Business Highlights
Revenue Mix: Orals:71%, Over The Counter :5%, Branded Oncology:7.6%, Injectables:17%
US Formulations
US revenue in Q1FY22 declined by 1.5% YoY to Rs. 2,681 crore, accounting 47% of consolidated revenue
Largest generics Company in the US by Rx dispensed (Prescriptions)
The company filed 8 ANDAs including 2 injectables with USFDA in Q1FY22 & received final approval for 4 ANDAs including 3 injectables in Q1FY22
The company has launched 5 products during the quarter
Europe revenue in Q1FY22 increased by 19.7% YoY to INR 1,583 crore, accounting 27.8% of consolidated revenue.
Revenue from Growth markets formulations in Q1FY22 increased by 13.7% YoY to INR 329 crore and accounted for 5.8% of revenue.
ARV business revenue for Q1FY22 was at INR 296 crore, decrease of 30.3% YoY and accounted for 5.1% of revenue
In Q1FY22, API business posted a revenue of INR 812 Cr and contributed 14.2% to the consolidated revenues
The company filed 1 DMF with the USFDA during the quarter.
The management is expecting US$3-3.5 crores in the first month from OTC brands, with revenue contribution not present in Q1. They expect US$3 crores per annum from ANDAs
Aurobindo acquired Cronus Pharma, focused on veterinary pharma products for 420 crores
Cronus has pipeline of 67 products (61 organically developed) out of which 40 are injectables and 27 are non-injectable. By April, 2023, the management expects the entire product line to be operationalized
Cronus generating sales of US$1.3 crores from six outsourced products and the management expects to grow this to US$2 crores
Cronus has an existing debt of 165 crore
Q1 global injectable sales: US$10.2 crores, FY22 target: US$60-70 crores
Download
